FluGen raises $12M

What does FluGen do?

FluGen, is a biopharmaceutical company which specializes on the prevention and treatment of seasonal and pandemic influenza worldwide. The company was founded in response to the need for significant improvement in existing methods of prevention and treatment of influenza infections. The company’s founded recognized an extraordinary chance to parlay their virology work and reverse genetics breakthrough into a successful biotech business. In just a few months, the company received a seed fund, a healthy evaluation and experienced supporters and board members.

How much FluGen was funded?

FluGen raised  $12M in Series A funding on August 25, 2015 from Knox Payments, Venture Investors, State of Wisconsin Investment Board and Wisconsin Alumni Research Foundation

Previous funding

$3.2M in Debt Financing on May 30, 2014

$3.3M in Venture round on Oct 6, 2011

What is next for FluGen?

The latest funding raised by the company will help it in providing the resources necessary for completing its preclinical testing, and for assessing the safety and immune responses induced by REDEE FLU in a phase 1 clinical trial of the influenza vaccine. It will also help in completion of the initial human clinical trial and for the preparation of a quadrivalent vaccine candidate.

The company has also announces the addition of Mr.C.Boyd Clarke and Dan Stinchcomb as independent directors. Dr.Stinchcomb was the CEO and co-founder of a privately held vaccine company, Inviragen which developed vaccines for hand, foot and oral diseases and for dengue and chikungunya.

More about FluGen

The company was founded in 2007 by Dr.Gabriele Neumann, Dr.Yoshihiro Kawaoka and Mr. Paul Radspinner in order to make a significant improvement in the existing methods of preventing and treating the infections caused by influenza virus. It has its headquarters in Madison, WI. Its vaccine, REDEE FLU is an effective vaccine in the world against all forms of the influenza virus.

.